Scientists have reported that a recently approved injectable drug for the treatment of eczema provides rapid relief from itching—one of the most distressing symptoms of this skin condition. This was shown by an analysis of clinical trial data published in the Journal of the European Academy of Dermatology and Venereology.

The drug, known as nemolizumab (brand name Nemluvio), is a monoclonal antibody that targets a receptor involved in activating inflammatory pathways responsible for severe itching in atopic dermatitis and a related condition, prurigo nodularis. This approach helps block a key mechanism that triggers intense itch in patients.

In the new analysis, researchers re-examined data from more than 2,300 participants in studies that formed the basis for the drug’s approval by the U.S. Food and Drug Administration (FDA) in 2024 for the treatment of moderate to severe eczema and prurigo nodularis.

The results showed that nemolizumab reduced itching within just two days: nearly 11% of patients with eczema reported significant relief compared with 3% in the placebo group. Among patients with prurigo nodularis, 17% experienced marked improvement versus just under 4% in the placebo group.

In addition, the drug improved sleep—an important treatment goal in chronic itch. Within two days, about 10% of patients with eczema and more than 13% of patients with prurigo nodularis reported noticeable improvements in sleep, while the rates in the placebo group were significantly lower.

Two weeks after the start of therapy, approximately one-quarter of patients with eczema and more than one-third of those with prurigo nodularis showed clinically meaningful improvements in both itch intensity and sleep quality.

The researchers emphasize that the drug’s rapid onset of action—reducing itch severity within the first days of treatment—is a key therapeutic goal for patients with moderate to severe eczema and prurigo nodularis.